

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

INTEGRATED BIOPHARMA INC
Form DEF 14A
November 06, 2006

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities and Exchange Act of 1934 (Amendment No.)

Filed by the Registrant |
Filed by a Party other than the Registrant |

Check the appropriate box:

| Preliminary Proxy Statement
 | Confidential, For Use of the
Commission Only (as permitted
by Rule 14a-6(e) (2))
 | Definitive Proxy Statement
 | Definitive Additional Materials
 | Soliciting Material Under Rule 14a-12

INTEGRATED BIOPHARMA, INC.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)

Payment of Filing Fee (Check the appropriate box):

| No fee required.
 | Fee computed on table below per Exchange Act Rules 14a-6(i) (4) and 0-11.

1. Title of each class of securities to which transaction applies:
2. Aggregate number of securities to which transaction applies:
3. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
4. Proposed maximum aggregate value of transaction:
5. Total fee paid:
 - | Fee paid previously with preliminary materials:
 - | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a) (2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
 - 1) Amount previously paid:
 - 2) Form, Schedule or Registration Statement No.:
 - 3) Filing Party:
 - 4) Date Filed:

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

INTEGRATED BIOPHARMA, INC.
225 Long Avenue
Hillside, New Jersey 07205

November 6, 2006

To Our Stockholders:

On behalf of the Board of Directors, it is our pleasure to invite you to attend the 2006 Annual Meeting of Stockholders of Integrated BioPharma, Inc. (the "Company"), which will be held at 9:00 a.m. local time, on November 22, 2006 at the Company's Executive Offices, 225 Long Avenue, Hillside, New Jersey 07205.

At the Annual Meeting, you will be asked to elect three Class I directors for a three year term and to ratify the appointment of independent auditors of the Company for the 2007 fiscal year. These matters are described in detail in the accompanying Notice of Annual Meeting of Stockholders and Proxy Statement. A proxy is included along with the Proxy Statement. These materials are being sent to stockholders on or about November 6, 2006.

It is important that your shares be represented at the Annual Meeting, whether or not you are able to attend. Accordingly, you are urged to sign, date and mail the enclosed proxy promptly. If you later decide to attend the Annual Meeting, you may revoke your proxy and vote your shares in person.

Sincerely,

/s/ E. Gerald Kay
E. Gerald Kay
Chief Executive Officer

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

INTEGRATED BIOPHARMA, INC.
225 Long Avenue
Hillside, New Jersey 07205

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON NOVEMBER 22, 2006

TO THE STOCKHOLDERS OF
INTEGRATED BIOPHARMA, INC.:

NOTICE IS HEREBY GIVEN that an Annual Meeting of Stockholders (the "Meeting") of Integrated BioPharma, Inc., a Delaware corporation ("INB" or the "Company"), will be held on November 22, 2006, at 9:00 a.m. local time, at the Company's Executive Offices, 225 Long Avenue, Hillside, New Jersey 07205, for the purpose of considering and acting upon the following proposals:

1. To elect three Class I directors for a three year term to serve until the 2009 Annual Meeting of Stockholders;
2. To ratify the appointment of Amper, Politziner & Mattia, P.C. as INB's independent accountants for the fiscal year ending June 30, 2007; and
3. The transaction of such other business as may properly come before the Meeting or any adjournment thereof.

Only holders of record of the Company's common stock, par value \$.002 per share ("Common Stock"), at the close of business on October 30, 2006 (the "Record Date"), are entitled to vote on the matters to be presented at the Annual Meeting. The number of shares of Common Stock outstanding on such date and entitled to vote was 13,537,419.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" PROPOSALS NO. 1 and NO. 2, TO BE PRESENTED TO INB STOCKHOLDERS AT THE ANNUAL MEETING.

By order of the Board of Directors.

/s/ Dina L. Masi
Dina L. Masi
Secretary

Hillside, New Jersey
November 6, 2006

It is important that your shares be represented at this meeting in order that a quorum may be assured. WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, YOU ARE URGED TO DATE, SIGN AND PROMPTLY MAIL THE ENCLOSED CARD IN THE POSTAGE PREPAID ENVELOPE PROVIDED AND TO DO SO IN ADEQUATE TIME FOR YOUR DIRECTIONS TO BE RECEIVED AND TABULATED PRIOR TO THE SCHEDULED MEETING.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

INTEGRATED BIOPHARMA, INC.
225 Long Avenue
Hillside, New Jersey 07205

PROXY STATEMENT 2006 ANNUAL MEETING OF STOCKHOLDERS

To be held on November 22, 2006

GENERAL INFORMATION

This Proxy Statement is furnished in connection with the solicitation of proxies on behalf of the Board of Directors of Integrated BioPharma, Inc. ("INB" or the "Company"), a Delaware corporation, to be voted at the 2006 Annual Meeting of Stockholders of the Company (the "Annual Meeting") to be held at the Company's Executive Offices, 225 Long Avenue, Hillside, New Jersey 07205 on November 22, 2006, at 9:00 a.m. local time, or at any postponement or adjournment thereof. This Proxy Statement, the Notice of Annual Meeting and the accompanying form of proxy are first being mailed to stockholders on or about November 6, 2006.

Only holders of record of the Company's common stock, par value \$.002 per share ("Common Stock"), at the close of business on October 30, 2006 (the "Record Date"), are entitled to vote on the matters to be presented at the Annual Meeting. The number of shares of Common Stock outstanding on such date and entitled to vote was 13,537,419.

Holders of Common Stock are entitled to one vote on each matter to be voted upon by the stockholders at the Annual Meeting for each share held.

At the Annual Meeting, stockholders will be asked to consider and vote upon proposals: (1) to elect three Class I directors for a three year term to serve until the 2009 Annual Meeting of Stockholders (the "Director Proposal") and (2) to ratify the appointment of Amper, Politziner, & Mattia, P.C., as INB's independent auditors for the fiscal year ending June 30, 2007 (the "Independent Auditors Proposal"). At the Annual Meeting, stockholders may also be asked to consider and take action with respect to such other matters as may properly come before the Annual Meeting.

QUORUM AND VOTE REQUIREMENTS

The presence, in person or by proxy, of holders of record of a majority of the shares of Common Stock issued and outstanding and entitled to vote is required for a quorum to transact business at the Annual Meeting, but if a quorum should not be present, the Annual Meeting may be adjourned from time to time until a quorum is obtained. Directors are elected by a plurality of votes cast. The Director Proposal and the Independent Auditors Proposal and all other matters to properly come before the Annual Meeting will be determined by the affirmative vote of the holders of a majority of the shares of Common Stock present, in person or by proxy, and entitled to vote at the Annual Meeting. Broker "non-votes" (i.e. proxies from brokers or nominees indicating that such persons have not received instructions from the beneficial owner or other persons entitled to vote shares as to a matter with respect to which the brokers or nominees do not have discretionary power to vote) and shares for which duly executed proxies have been received but with respect to which holders of shares have abstained from voting will be treated as present for purposes of

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

determining the presence of a quorum at the Annual Meeting. Abstentions and broker non-votes have no impact on the election of directors except to reduce the number of votes for the nominees. With respect to all other proposals, broker non-votes are not counted as votes and, therefore, will not be included in vote totals and abstentions will have the effect of a negative vote against such other proposals.

SOLICITATION AND REVOCATION

PROXIES IN THE FORM ENCLOSED ARE BEING SOLICITED BY, AND ON BEHALF OF, THE BOARD OF DIRECTORS. THE PERSONS NAMED IN THE ACCOMPANYING FORM OF PROXY HAVE BEEN DESIGNATED AS PROXIES BY THE BOARD OF DIRECTORS.

All Common Stock represented by properly executed proxies which are returned and not revoked prior to the time of the Annual Meeting will be voted in accordance with the instructions, if any, given thereon. If no instructions are provided in an executed proxy, it will be voted (1) FOR the Director Proposal; (2) FOR the Independent Auditors Proposal, and in accordance with the proxy holder's discretion as to any other business raised at the Annual Meeting. Any stockholder who executes a proxy may revoke it at any time before it is voted by delivering to the Company a written statement revoking such proxy, by executing and delivering a later dated proxy, or by voting in person at the Annual Meeting. Attendance at the Annual Meeting by a stockholder who has executed and delivered a proxy to the Company shall not in and of itself constitute a revocation of such proxy.

The Company will bear its own cost for the solicitation of proxies. Proxies will be solicited initially by mail. Further solicitation may be made by directors, officers, and employees of the Company personally, by telephone, or otherwise, but any such person will not be specifically compensated for such services. The Company also intends to make, through banks, brokers or other persons, a solicitation of proxies of beneficial holders of the Common Stock. Upon request, the Company will reimburse brokers, dealers, banks and similar entities acting as nominees for reasonable expenses incurred in forwarding copies of the proxy materials relating to the Annual Meeting to the beneficial owners of Common Stock which such persons hold of record.

PROPOSAL NO. 1 ELECTION OF DIRECTORS

The Company's Board of Directors is currently composed of ten (10) directors divided into three classes of directors serving staggered 3-year terms.

The members of Class I, whose terms of office expire in 2009, are Mr. E. Gerald Kay, Ms. Riva Sheppard and Mr. Carl DeSantis.

The members of Class II, whose terms of office expire in 2008, are Ms. Christina Kay, Mr. Robert Canarick and Mr. Robert Kay.

The members of Class III, whose terms of office expire in 2007, are Mr. Seymour Flug, Mr. Glenn Chang, Mr. Zarko Kraljevic and Dr. Vidadi Yusibov.

The stockholders will consider and vote upon the election of Mr. E. Gerald Kay, Ms. Riva Sheppard and Mr. Carl DeSantis to serve their respective terms.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

Unless a shareholder WITHHOLDS AUTHORITY, a properly signed and dated proxy will be voted FOR the election of the nominees, unless the proxy contains contrary instructions. The Board of Directors knows of no reason why any of its nominees will be unable or will refuse to accept election. If any nominee becomes unable or refuses to accept election, the Board of Directors will either reduce the number of directors to be elected or select a substitute nominee. If a substitute nominee is selected, proxies will be voted in favor of such nominee.

The following table sets forth certain information with respect to the members of INB's Board of Directors during the fiscal year ended June 30, 2006.

	Age ---	Class of Directors -----	Dire Sin ----
E. Gerald Kay Served as Chairman of the Board and President of the Company, and its predecessor since 1980, and was president until May 1999. On May 9, 2003 he became Chief Executive Officer.	70	Class I	198
Riva Sheppard Served as Vice President and director of the Company since May 1991. Ms. Sheppard is the daughter of E. Gerald Kay and the sister of Christina Kay.	39	Class I	199
Carl DeSantis Served as director of the Company since 2003. Mr. DeSantis has served as Chairman of CDS International Holdings, Inc. since June of 2001. Prior to that he was Chairman of Rexall Sundown, Inc.	67	Class I	200
Christina Kay Served as Vice President and director of the Company since December 1994. Ms. Kay is the daughter of E. Gerald Kay and the sister of Riva Sheppard.	36	Class II	199
Robert Canarick Served as a director of the Company since December 1994. From January 1998 until August of 2001 he has served as general counsel of NIA Group, LLC, an all lines independent insurance agency. From August 2001 he has served as President of Links Insurance Services, LLC. Mr. Canarick is a Certified Public Accountant and Attorney.	56	Class II	199
Seymour Flug Served as President of the Company from May 1999 until May 9, 2003. Prior to 1999, he was Chairman of the Board of Diners Club International.	71	Class III	200
Robert B. Kay Served as a director of the Company since 2003. Since 2002 served as Chairman of Paxis Pharmaceuticals, Inc. Prior to that he was a founding partner of the New York-	66	Class II	200

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

based law firm of Kay, Collyer & Boose LLP. Mr. Kay is the brother of E.Gerald Kay.

Glenn Chang Served as a director of the Company since 2003. Since 1999 he has been Director, Executive Vice President and Chief Financial Officer of the First American International Bank, Brooklyn, N.Y. Prior to the founding of the Bank he spent almost 20 years at Citibank as Vice President. Mr. Chang is a Certified Public Accountant.	58	Class III	200
Zarko Kraljevic Served as a director of the Company since 2003. Since 1972 has served as President and CEO of Diners Club of Eastern Europe.	78	Class III	200
Vidadi M. Yusibov Served as a director of the Company since 2006. Since 2001 he has served as Scientific Director and Executive Director of Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware. Prior to his association with Fraunhofer he was an assistant professor in the Department of microbiology and immunology at Thomas Jefferson University, Philadelphia, Pennsylvania.	48	Class III	200

Recommendation and Vote

Approval of the election of these nominees for directors requires the affirmative vote of a majority of the shares of Common Stock present, in person or by proxy, at the Annual Meeting.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE FOR THE NOMINEES FOR DIRECTORS LISTED ABOVE.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), requires the Company's directors, executive officers and holders of more than 10% of the Company's common stock to file reports of ownership and changes in ownership of common stock with the Securities and Exchange Commission. Certain persons required to file such reports failed to do so on a timely basis as required by Section 16(a) of the Exchange Act. Messrs. R.Kay, Canarick, Kraljevic, and Chang filed three reportable transactions late, Ms. Kay, Ms. Sheppard and Mr. Flug each filed two reportable transactions late, and Dr. Yusibov filed one reportable transaction late.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding the number of shares of common stock of Integrated BioPharma beneficially owned on October 10, 2006, by:

* each person who is known by Integrated BioPharma to beneficially own five percent (5%) or more of the common stock of Integrated BioPharma;

* each of the directors and executive officers of Integrated BioPharma; and

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

* all of Integrated BioPharma's directors and executive officers, as a group.

The address of each of the persons listed below is c/o Integrated BioPharma Inc., 225 Long Avenue, Hillside, New Jersey 07205.

Name of Beneficial Owner	Number of Shares Beneficially Owned (1)	Percent of Shares Beneficially Owned (2)
E. Gerald Kay	5,779,582 (3)	38.8%
Carl DeSantis	2,360,417 (4)	17.2%
Riva Sheppard	1,319,467 (5)	9.3%
Christina Kay	1,319,467 (5)	9.3%
Seymour Flug	1,266,033 (6)	8.8%
Robert B. Kay	1,219,629 (7)	8.8%
Robert Canarick	203,533 (8)	1.5%
Zarko Kraljevic	75,000 (9)	0.6%
Glenn Chang	75,000 (9)	0.6%
Dina L. Masi	50,000 (10)	0.4%
Vidadi M. Yusibov	23,500 (11)	0.2%
Directors and executive officers as a group (11 persons)	13,691,628 (12)	74.8%

-
- (1) Unless otherwise indicated, includes shares owned by a spouse, minor children, by relatives sharing the same home, and entities owned or controlled by the named person. Also includes shares if the named person has the right to acquire such shares within 60 days after October 10, 2006, by the exercise of warrant, stock option or other right. Unless otherwise noted, shares are owned of record and beneficially by the named person.
 - (2) Based upon 13,466,030 shares of common stock outstanding on October 10, 2006.
 - (3) Includes (i) 819,629 shares of common stock held by EGK LLC, of which Mr. Kay is the manager, and (ii) 1,336,546 shares of common stock issuable upon exercise of presently exercisable stock options. Shares dispositive power with Christina Kay with respect to 169,358 shares of common stock and with Riva Kay Sheppard with respect to 169,358 shares of common stock.
 - (4) Includes (i) 819,629 shares owned by CDS Group Holdings, LLC, of which Mr. DeSantis is the manager, (ii) 25,000 shares of common stock issuable upon exercise of presently exercisable stock options and (iii) 175,000 shares of common stock issuable upon exercise of presently exercisable warrants.
 - (5) Includes 616,666 shares of common stock issuable upon exercise of presently exercisable stock options. Shares dispositive power with E. Gerald Kay with respect to 169,358 shares of common stock.
 - (6) Includes 850,000 shares of common stock issuable upon exercise of presently exercisable stock options.
-

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

- (7) Includes (i) 819,629 shares of common stock held by EVJ LLC, of which Mr. Kay is the manager, and (ii) 300,000 shares of common stock issuable upon exercise of presently exercisable stock options.
- (8) Includes 150,000 shares of common stock issuable upon exercise of presently exercisable stock options.
- (9) Includes 50,000 shares of common stock issuable upon exercise of presently exercisable stock options.
- (10) Includes 50,000 shares of common stock issuable upon exercise of stock options exercisable within 60 days of the date hereof.
- (11) Includes 13,500 shares of common stock issuable upon exercise of presently exercisable stock options.
- (12) Includes (i) 4,618,378 shares of common stock issuable upon exercise of presently exercisable stock options, (ii) 175,000 shares of common stock issuable upon exercise of presently exercisable warrants and (iii) 50,000 shares of common stock issuable upon exercise of stock options exercisable within 60 days of the date hereof.

Securities Authorized for Issuance Under Equity Compensation Plans

The following table includes information as of June 30, 2006 relating to the Company's stock option plans, which comprise all of the Company's equity compensation plans. The table provides the number of securities to be issued upon the exercise of outstanding options under such plans, the weighted-average exercise price of such outstanding options and the number of securities remaining available for future issuance under such plans.

Equity Compensation Plan Information

	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	-----	-----	-----
Equity compensation plans approved by security holders	6,085,177	\$ 3.37	
Equity compensation plans not approved by security holders	-	-	
Totals	6,085,177	\$ 3.37	
	=====	=====	=====

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

DIRECTORS

The Board of Directors held three meetings during the fiscal year ended June 30, 2006. All directors attended at least 67% of the meetings of the Board and one member of the audit committee was unable to attend all such committee meetings held during the fiscal year ended June 30, 2006 on which he or she served.

For the fiscal year ended June 30, 2006, each independent Director who was a Director as of the beginning of the fiscal year was granted 25,000 options (an aggregate of 75,000 options) under the Company's 2001 Stock Option Plan, with an exercise price of \$3.99 which represents the fair market value of the shares of common stock as of the grant date. Each option vest one year from the date of grant and will expire in ten years from the date of grant. No compensation was paid to any director for his or her services to the Board of Directors or any committee who was also an officer and/or significant shareholder. The only standing committee of the Board of Directors is the Audit Committee, whose members are Messrs. Canarick, Chang, and Kraljevic and Dr. Yusibov. The Audit Committee periodically consults with the Company's management and independent public accountants on financial matters, including the Company's internal financial controls and procedures. The Audit Committee met four times in Fiscal 2006 and two-thirds of the members attended all the meetings. Dr. Yusibov attended all the meetings that were held subsequent to his appointment to the Audit Committee.

The Company does not have a standing nominating committee or compensation committee. With respect to nominating and compensation matters, the entire Board performs these functions. At such time, if any, as the Board composition changes or the Board otherwise deems appropriate, the Company may establish a separate nominating committee or compensation committee. As a result, the entire Board participates in the consideration of Board nominees and nominated the candidates for election named in this Proxy Statement.

The Company has determined that due to the beneficial ownership by E. Gerald Kay and certain of his family members of greater than 50% of the Common Stock of the Company outstanding as of October 10, 2006, the Company is a "controlled company" as defined in the American Stock Exchange listing standards. As such, the Company is exempt from certain requirements of the American Stock Exchange listing standards, including the requirement to maintain a majority of independent directors on the Company's Board of Directors and the requirements regarding the determination of compensation of executive officers and the nomination of directors by independent directors.

EXECUTIVE OFFICERS

The following individual is an executive officer of the Company but is not a Director or Nominee for Director:

Dina L. Masi, age 45, is Senior Vice President, Chief Financial Officer and Secretary of the Company. Ms. Masi joined the Company on November 17, 2005. Previously, Ms. Masi most recently operated a financial services consulting firm, DLM Accounting and Financial Services, LLC, providing accounting and financial services to small business owners and SEC registrants from May 2005 to November 2005. From June 2002 to December 2004, Ms. Masi served as the Chief Financial Officer and Senior Vice President of Prescott Funding, LLC, a licensed residential mortgage lender specializing in non-conforming consumer lending. Ms. Masi also served as the Chief Financial Officer and Senior Vice President of

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

Fintek, Inc., a privately owned financial consulting services company, from July 2001 to September 2005 and as Management Information Officer from February 1998 to July 2001. Prior to that, Ms. Masi was the Chief Financial Officer and Executive Vice-President of The Aegis Consumer Funding Group, Inc., a publicly-traded consumer finance company that specialized in sub-prime automobile receivables, from July 1992 to January 1998. Prior to her time at Aegis, Ms. Masi was with BDO Seidman, LLP.

EXECUTIVE COMPENSATION

The following table shows, for the fiscal years ended June 30, 2006, 2005, 2004, certain compensation information as to the Chief Executive Officer and each of the next four most highly compensated executive officers of the Company who served as an executive officer during the fiscal year ended June 30, 2006, and whose salary and bonus exceeded \$100,000 in 2006 (the "Named Executive Officers").

SUMMARY COMPENSATION TABLE

Name and Principal Position -----	Year ----	Annual Compensation -----		Long Term Com ----- Securities U Stock O -----
		Salary -----	Bonus -----	
E. Gerald Kay Chairman of the Board	2006	\$ 127,875	\$ -	
	2005	97,875	-	100,0
	2004	97,500	-	100,0
Eric Friedman Chief Financial Officer and Vice President (3)	2006	200,769	-	
	2005	200,769	-	100,0
	2004	200,000	-	100,0
Robert B. Kay President and Chief Executive Officer, Paxis Pharmaceuticals, Inc.	2006	25,096	-	
	2005	24,996	-	100,0
	2004	24,996	-	100,0
Riva Sheppard Executive Vice President	2006	115,414	-	
	2005	109,980	-	100,0
	2004	109,980	-	100,0
Christina Kay Executive Vice President	2006	115,414	-	
	2005	108,325	-	100,0
	2004	99,994	-	100,0
Dina L. Masi Chief Financial Officer and Senior Vice President -----	2006	111,528	-	50,0

- (1)The disclosed amount includes the Company's matching contributions under the Company's 401(K) plan.
- (2)The Company also provides the individuals with the use of a company car.
- (3)Mr. Friedman resigned as an officer of the Company on April 13, 2006.
- (4)Represents consulting fees paid to EVJ, LLC, of which Mr. Kay is the manager.
- (5)Represents consulting fees paid to DLM Accounting and Financial Services, LLC, of which Ms. Masi is the sole member.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

OPTION/SAR GRANTS DURING THE FISCAL YEAR ENDED JUNE 30, 2006

The following table sets forth individual grants of stock options by INB pursuant to the Integrated Health Technologies, Inc. 2001 Stock Option Plan to the Named Executive Officers during the fiscal year ended June 30, 2006.

Name	Securities Options Granted (#) (1)	% of Total Granted to Employees in Fiscal Year	Exercise Price (2)	Expiration Date
Dina L. Masi	50,000	49.0%	\$ 3.13	November 17, 2015

(1) The date of grant for these options was November 17, 2005, which become exercisable on November 17, 2006.

(2) The exercise price of the options is equal to the fair market value of the shares of common stock of the Company on the date of grant.

AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION/SAR VALUES

The following table sets forth information with respect to the Named Executive Officers concerning the exercise of options during the fiscal year ended June 30, 2006 and unexercised options held at the end of the fiscal year ended June 30, 2006 based on the last sale price of a share of common stock on June 30, 2006 of \$8.87.

Name	Acquired on Exercise (#)	Value Realized (1) (\$)	Number of Securities Underlying Unexercised Options at Fiscal Year End (#) Exercisable/ Unexercisable	Value of Unexercised In-the-Money Options at Fiscal Year End Exercisable/ Unexercisable (\$)
E. Gerald Kay	-	-	1,436,546 / -0-	10,263,511 / -
Eric Friedman (3)	215,000	1,639,050	466,666 / -0-	2,097,328 / -
Robert B. Kay	-	-	400,000 / -0-	1,861,000 / -
Riva Kay Sheppard	-	-	716,666 / -0-	4,206,828 / -
Christina Kay	-	-	716,666 / -0-	4,206,828 / -
Dina L. Masi	-	-	-0- / 50,000	-0- / 287,000

(1) Represents the aggregate market value of the shares converted by the options on the date of exercise less the aggregate price paid by the executive.

(2) Based on the fair market value of the shares of Common Stock on June 30, 2006 (\$8.87), less the exercise price.

(3) These shares were acquired subsequent to Mr. Friedman resigning as an officer of the Company on April 13, 2006.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

TOTAL SHAREHOLDER RETURN GRAPH

	6/01	6/02	6/03	6/04	6/05	6/06
Integrated BioPharma, Inc.	100.00	200.00	3,561.90	3,885.71	1,804.76	4,223.81
S&P 500	100.00	81.72	80.46	94.19	98.36	104.87
Russell 3000	100.00	83.04	82.16	97.30	103.32	111.22

 *\$100.00 invested on June 30, 2001 in stock or index. Fiscal year ended June 30.

CERTAIN RELATIONSHIPS AND TRANSACTIONS

Warehouse and office facilities are leased from Vitamin Realty Associates, L.L.C., a limited liability company, which is 90% owned by E. Gerald Kay, Riva Sheppard and Christina Kay (all stockholders and directors of the Company) and 10% owned by Eric Friedman, the Company's former Chief Financial Officer. The lease was effective on January 10, 1997 and provides for minimum annual rentals of \$346,000 through January 10, 2002, plus increases in real estate taxes and building operating expenses. At its option, the Company has the right to renew the lease for an additional five-year period. On April 28, 2000 the lease was amended reducing the square footage and extending the lease to May 31, 2015.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

PROPOSAL NO. 2 RATIFICATION OF THE APPOINTMENT OF INDEPENDENT AUDITORS

The Board of Directors of INB has appointed the firm of Amper, Politziner & Mattia, P.C., independent auditors, to audit the consolidated financial statements of Integrated BioPharma, Inc. and its subsidiaries for the fiscal year ending June 30, 2007, subject to ratification by the INB Stockholders.

A member of Amper, Politziner & Mattia, P.C. is expected to be present at the Annual Meeting and to be provided with the opportunity to make a statement if such member desires to do so and to be available to respond to appropriate questions from shareholders.

Representatives of Amper, Politziner & Mattia, P.C. normally attend most meetings of the Audit Committee. The Audit Committee's policy is to pre-approve all audit and permissible non-audit services provided by the independent auditors. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one fiscal quarter and any pre-approval is detailed as to the particular service or category of services. The independent auditor and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent auditor in accordance with this pre-approval.

The Audit Committee, on an annual basis, reviews the services performed by Amper, Politziner & Mattia, P.C., and reviews and approves the fees charged by Amper, Politziner & Mattia, P.C.

Audit Fees

The aggregate fees billed for professional services rendered for the audit of the Company's annual financial statements for the fiscal year ended June 30, 2006 and 2005 and for the reviews of the financial statements included in the Company's Quarterly Reports on Form 10-Q in the fiscal year ended June 30, 2006 and 10-QSB in the fiscal year ended June 30, 2005 were \$186,625 and \$172,500, respectively, all of which are attributable to Amper, Politziner & Mattia, P.C.

Financial Information Systems Design and Implementation Fees

Amper, Politziner & Mattia, P.C. did not render professional services relating to financial information systems design and implementation for the fiscal years ended June 30, 2006 and 2005.

Tax Fees and All Other Fees

Amper, Politziner & Mattia, P.C. did not receive any fees for tax services nor for other services for the fiscal years ended June 30, 2006 and 2005.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

Recommendation and Vote

Approval of the Independent Auditors Proposal requires the affirmative vote of a majority of the shares of Common Stock present, in person or by proxy, at the Annual Meeting.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE APPROVAL
OF THE INDEPENDENT AUDITORS PROPOSAL.

AUDIT COMMITTEE REPORT

The Audit Committee of the Board of Directors of the Company (the "Audit Committee") is composed of four (4) directors. Each of the four members of the committee are independent. The Board of Directors has adopted an Audit Committee Charter. Management is responsible for the Company's internal control and financial reporting process. The Company's independent public accountants are responsible for performing an independent audit of the Company's consolidated financial statements in accordance with generally accepted auditing standards and to issue a report thereon. The Audit Committee's responsibility is to monitor and oversee these processes.

In this context, the Audit Committee has met and held discussions with Management and the Company's independent public accountants. Management represented to the Audit Committee that the Company's consolidated financial statements were prepared in accordance with generally accepted accounting principles, and the Audit Committee has reviewed and discussed the consolidated financial statements with Management and the Company's independent public accountants. The Audit Committee discussed with the independent public accountants matters required to be discussed by Statement of Auditing Standards Numbers 90 and 61 (communication with Audit Committees). The Company's independent public accountants also provided to the Audit Committee the written disclosures required by Independence Standard No. 1 (independence discussions with Audit Committee), and the Audit Committee discussed with the independent public accountants that firm's independence. The Audit Committee has also considered whether the independent auditors' provision of information technology and other non-audit services to the Company is compatible with the auditor's independence.

Based upon the Audit Committee's discussions with Management and the independent public accountants and the Audit Committee's review of the representation of management and the report of the independent public accountants, the Audit Committee recommended that the Board of Directors include the audited consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended June 30, 2006 filed with the Securities and Exchange Commission.

The foregoing has been approved by all members of the Audit Committee.

Glenn Chang
Robert Canarick
Zarkof Kraljevic
Dr. Vidadi M. Yusibov

Edgar Filing: INTEGRATED BIOPHARMA INC - Form DEF 14A

STOCKHOLDER PROPOSALS AND COMMUNICATIONS

Stockholder proposals to be included in the Company's proxy statement with respect to the 2007 Annual Meeting of Stockholders must be received by the Company at its Executive Offices located at 225 Long Avenue, Hillside, New Jersey 07205 no later than July 5, 2007. All such proposals are subject to the applicable rules and requirements of the Securities and Exchange Commission.

The Board of Directors does not have a formal process for stockholders to send communications (including director nominations) to the Board. Due to the infrequency of stockholder communications to the Board, the Board does not believe that a formal process is necessary. Written communications to the Board may be sent to the Board at the Company's chief executive offices at Integrated BioPharma, Inc., 225 Long Avenue, New Jersey 07205, and the Company will promptly circulate such communications to all members of the Board (or to those particular directors to whom such communication is specifically addressed). A shareholder who intends to nominate an individual for election to the Board of Directors (other than a candidate proposed by the Board of Directors) must do so in accordance with the foregoing procedures.

DISCRETIONARY AUTHORITY

A duly executed proxy given in connection with the Company's 2006 Annual Meeting of Stockholders will confer discretionary authority on the proxies named therein, or any of them, to vote at such meeting on any matter of which the Company does not have written notice on or before September 12, 2006, which is forty-five (45) days prior to the date on which the Company is first mailing its proxy materials for its 2006 Annual Meeting of Stockholders, without advice in the Company 2006 Proxy Statement as to the nature of such matter.

OTHER BUSINESS OF THE MEETING

The Company is not aware of any matters to come before the Annual Meeting other than those stated in this Proxy Statement. However, in as much as matters of which management of the Company is not now aware may come before the Annual Meeting or any adjournment, the proxies confer discretionary authority with respect to acting thereon, and the persons named in such proxies intend to vote, act and consent in accordance with their discretion with respect thereto.

ADDITIONAL INFORMATION

COPIES OF THE COMPANY'S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED JUNE 30, 2006 MAY BE OBTAINED WITHOUT CHARGE BY ANY STOCKHOLDER TO WHOM THIS PROXY STATEMENT IS SENT, UPON WRITTEN REQUEST TO THE SECRETARY, INTEGRATED BIOPHARMA, INC., 225 LONG AVENUE, HILLSIDE, NEW JERSEY 07205.

By order of the Board of Directors

/s/ E. Gerald Kay
E. Gerald Kay
Chief Executive Officer

November 6, 2006